Presentation is loading. Please wait.

Presentation is loading. Please wait.

Inderpal S. Sarkaria, MD, Maureen F

Published byNikolett Balla Modified over 5 years ago

Similar presentations

Presentation on theme: "Inderpal S. Sarkaria, MD, Maureen F"— Presentation transcript:

1 Epidermal Growth Factor Receptor Signaling in Adenocarcinomas With Bronchioloalveolar Components 
Inderpal S. Sarkaria, MD, Maureen F. Zakowski, MD, Duykhanh Pham, MD, Michael Hezel, BA, Michael I. Ebright, MD, Shaokun Chuai, MA, Ennapadam S. Venkatraman, PhD, Mark G. Kris, MD, Valerie W. Rusch, MD, Bhuvanesh Singh, MD  The Annals of Thoracic Surgery  Volume 85, Issue 1, Pages (January 2008) DOI: /j.athoracsur Copyright © 2008 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Representative examples of marker expression in tumor cohort. (EGFR = epidermal growth factor receptor; p-AKT = phosphorylated murine thymoma viral oncogene homolog; PTEN = phosphatase and tensin homolog; p-ERK = phosphorylated extracellular signal related kinase.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2008 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 (A) Multidimensional scaling of study markers in bronchioloalveolar carcinoma. (B) Simplified schematic of known epidermal growth factor receptor (EGFR) signaling through phosphatidylinositol 3′ kinase (PI3K)-dependent and ras-dependent pathways. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2008 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Overall survival and disease-free interval analyses by epidermal growth factor receptor status. The cumulative number of patients at risk (N at Risk) by year is represented by positive (pos) and negative (neg) immunophenotype status. Crosshatch marks represent censured data points. (A, B) OS and DFI for all tumors (median follow-up 73.0 and 31.5 months, respectively); (C, D) OS and DFI for BAC (median follow-up 49.1 and 25.7 months, respectively); (E, F) OS and DFI for adeno/BAC (median follow-up 81.5 and 45.3 months, respectively). (OS = overall survival; DFI = disease free interval; EGFR = epidermal growth factor receptor; BAC = bronchioloalveolar carcinoma; adeno/BAC = adenocarcinoma, mixed subtype, with bronchioloalveolar components.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2008 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Inderpal S. Sarkaria, MD, Maureen F"

Similar presentations

Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
Photodynamic Laser Therapy for Lesions in the Airway

Photodynamic Laser Therapy for Lesions in the Airway
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Giant Transdiaphragmatic Intercostal Hernia

Giant Transdiaphragmatic Intercostal Hernia
Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,

Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,
Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.
Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K

Masatsugu Hamaji, MD, Stephen D. Cassivi, MD, K
Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations  Tae Jung Kim, MD, PhD, Choon-Taek.

Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations  Tae Jung Kim, MD, PhD, Choon-Taek.
The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis  Dong Zhou, MD, Xu-Feng Deng, MD, Quan-Xing.

The Effectiveness of Postoperative Radiotherapy in Patients With Completely Resected Thymoma: A Meta-Analysis  Dong Zhou, MD, Xu-Feng Deng, MD, Quan-Xing.
Bryan A. Whitson, MD, Blake A

Bryan A. Whitson, MD, Blake A
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C
Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma  Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,

Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma  Tetsuya Isaka, MD, Haruhiko Nakayama, MD, PhD,
Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.

Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.
Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.

Epidermal Growth Factor Receptor Is a Prognosis Predictor in Patients With Esophageal Squamous Cell Carcinoma  Wencheng Zhang, MD, Hongxia Zhu, MD, Xiao.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Michael L. Bailey, MBBS, Sven M. Richter, MD, Daniel V

Michael L. Bailey, MBBS, Sven M. Richter, MD, Daniel V
Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma  R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,

Second Primary Lung Cancers: Smokers Versus Nonsmokers After Resection of Stage I Lung Adenocarcinoma  R. Taylor Ripley, MD, Robert R. McMillan, MD, MPH,
Loretta Erhunmwunsee, MD, Brian C

Loretta Erhunmwunsee, MD, Brian C
Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer  Servet Bölükbas,

Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer  Servet Bölükbas,

Similar presentations

Ads by Google